<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693862</url>
  </required_header>
  <id_info>
    <org_study_id>2939115</org_study_id>
    <nct_id>NCT00693862</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study With Repeated Doses of Stalevo</brief_title>
  <official_title>Levodopa Concentration Profile After Repeated Doses of Stalevo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that higher minimum concentration values are obtained
      following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment
      with corresponding dosing regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Blood samples collected frequently on day 4 of both periods</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Stalevo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>levodopa/carbidopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa, carbidopa, entacapone</intervention_name>
    <arm_group_label>Stalevo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa, carbidopa</intervention_name>
    <arm_group_label>levodopa/carbidopa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained

          -  Male or female patients with idiopathic Parkinson's disease with either a stable drug
             response or mild and predictable end-of-dose wearing-off symptoms.

          -  Hoehn and Yahr stage 1-2.5 performed during the &quot;ON&quot; state.

          -  Treatment with 3-5 daily doses of levodopa/DDCI ± entacapone with a total daily
             levodopa dose in the range of 300-600 mg.

          -  Unchanged levodopa/DDCI ± entacapone and other antiparkinsonian medication (dopamine
             agonists, monoamine oxidase B (MAO-B) inhibitor, amantadine and/or anticholinergics
             with doses recommended by the manufacturer), if any, for at least 2 weeks prior to the
             first treatment period.

          -  Age within 30-72 years, inclusive.

        Exclusion Criteria:

          -  Secondary or atypical parkinsonism.

          -  Patients with moderate to marked wearing-off symptoms or any unpredictable
             &quot;OFF&quot;-periods.

          -  Patients with treatment-related peak-dose dyskinesia.

          -  Change in dose strength, daily dose or dosing frequency of any medicinal products used
             to treat other medical conditions than Parkinson's disease within 2 weeks.

          -  Use of any iron preparations or other chelating agents.

          -  Patients with a history of a laboratory abnormality consistent with, or clinically
             significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological
             or psychiatric disorder or any other major concurrent illness, which may influence the
             outcome of the study.

          -  History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis,
             malignant melanoma, narrow-angle glaucoma or pheochromocytoma.

          -  Any abnormalities in laboratory values, vital signs or electrocardiogram (ECG) with
             clinical relevance.

          -  Patients using any antiparkinsonian drugs for rescue medication (including soluble
             levodopa formulations).

          -  Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO
             inhibitors.

          -  Known hypersensitivity to active substances or to any of the excipients of the study
             drugs.

          -  Participation in other drug studies within 60 days prior to study entry

          -  Unsuitable veins for repeated venopuncture.

          -  Blood donation or loss of significant amount of blood within 60 days prior to the
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta Hänninen, M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NEURO</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacokinetics laboratory/Department of Pharmacology and Toxicology</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>June 6, 2008</last_update_submitted>
  <last_update_submitted_qc>June 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jutta Hänninen, Clinical Study Manager</name_title>
    <organization>Orion Corporation, Orion Pharma</organization>
  </responsible_party>
  <keyword>Focus of the study is pharmacokinetics of the study drug</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

